Investor relations – Syn2bio

Go to navigation
Go to content

Quotations

Melhus Company Ltd

Książek Holding Sp. z o.o.

Nationale-Nederlanden PTE SA

Other shareholders

Shareholder	Number of shares	Share in share capital	Number of votes	Share in total number of votes
Melhus Company Ltd	2 047 380	23,45%	2 047 380	23,45%
Książek Holding Sp. z o.o.	1 376 143	15,76%	1 376 143	15,76%
Nationale-Nederlanden PTE SA	635 176	7,28%	635 176	7,28%
Other shareholders	4 670 430	53,51%	4 670 430	53,51%
TOTAL	8 729 129	100%	8 729 129	100%

Latest reports

Published	Report	Description
13.08.2026	Q3 FY2025	Standalone financial statement of Syn2bio for Q3 FY2025 (01.10.2025-30.06.2026) / Polish	Download
13.08.2026	Q3 FY2025	Selected financial data for Q3 FY2025 / Polish	Download
30.06.2026	H1 FY2025	Report on the activities of Syn2bio for H1 FY2025 (01.10.2025-30.03.2026) / Polish	Download

Current reports Periodic reports

Upcoming events

13.08.2026

Publication of standalone quarterly report (SA-Q) for Q3/FY2025 (Q2 of the calendar year 2026)

14.07.2026

Beginning of closed period before publication of quarterly results

30.06.2026

Publication of standalone interim report (SA-P) for H1/ FY2025 (Q4 of the calendar year 2025 and Q1 of the calendar year 2026)

Latest news

Syn2bio sums up the third quarter of the financial year: Trials of the SYN2 cardiotracer in Europe according to schedule, preparations to launch trials in the US

Investor relations
Press releases

Syn2bio publishes its first periodic report

Investor relations
Press releases

Extraordinary Shareholders’ Meeting on 19 May 2026

Corporate news
Investor relations

Investor relations

phone: +48 22 327 09 10

e-mail: ir@syn2bio.pl